
PGEN Earnings
Precigen Inc
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Precigen Inc(PGEN) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Precigen Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
FY2025Q2 | 2025-08-13 | After Hours | -0.14 | - | - | 1,000K | - | - | - | - |
FY2025Q1 | 2025-05-14 | After Hours | -0.08 | -0.07 | +12.50 | 500.00K | 1.34M | +168.20 | +2.34 | +10.16 |
FY2024Q4 | 2025-03-19 | After Hours | -0.06 | - | - | 3.00M | 1.19M | -60.33 | +0.56 | -10.06 |
FY2024Q3 | 2024-11-14 | - | -0.08 | -0.09 | -12.50 | 1.28M | 953.00K | -25.55 | -4.35 | -8.70 |
FY2024Q2 | 2024-08-14 | After Hours | -0.09 | -0.10 | -11.11 | 1.28M | 717.00K | -43.98 | -4.46 | +6.25 |
FY2024Q1 | 2024-05-14 | - | -0.09 | -0.10 | -11.11 | 1.48M | 1.07M | -28.04 | +1.48 | +2.96 |
FY2023Q4 | 2024-03-19 | - | -0.08 | -0.09 | -12.50 | 1.70M | 1.23M | -27.76 | +3.60 | +1.44 |
FY2023Q2 | 2023-08-09 | - | -0.10 | -0.08 | +20.00 | 2.18M | 1.77M | -18.94 | +6.90 | +31.90 |
- | 2023-05-10 | - | -0.08 | -0.10 | -25.00 | - | - | - | -3.97 | -3.17 |
- | 2022-11-09 | - | 0.10 | -0.04 | -140.00 | - | - | - | -8.13 | +21.87 |
PGEN Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Precigen Inc reported performance for FY2025Q2, announced on 2025-08-13. The company achieved an EPS of , compared to analyst estimates of -0.14 by % . Revenue for the quarter reached 0.00 compared to expectations of 1,000K by % .
The stock price reacted with a % one-day change and a % five-day change following the earnings release. These movements reflect market reaction in Precigen Inc growth trajectory and strategic initiatives.
PGEN Earnings Forecast
Looking ahead, Precigen Inc(PGEN) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q2 project quarter revenue of 666.67K and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Downward by -24.95%, while EPS estimates have been Revise Downward by -33.33%. For the upcoming , revenue estimates have been adjusted Go Up by 41.48% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Precigen Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between PGEN's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Downward

-24.95%
In Past 3 Month
Revenue Estimates for Q2 2025
Revise Downward

-33.33%
In Past 3 Month
Stock Price
Go Up

+41.48%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:13.70M
--
EPS Estimate-Annual FY 2025:0
—
Stock Price1.91
PGEN Revenue and EPS Performance: A Historical Perspective
Precigen Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-08-13,After Hours):
EPS: (Actual) vs.-0.14 (Estimate) (%)
Revenue: 0.00 (Actual) vs. 1,000K (Estimate) (%)
Price Reaction: %(1-Day), %(5-Day)
FY2025Q1 (2025-05-14,After Hours):
EPS: -0.07 (Actual) vs.-0.08 (Estimate) (12.50%)
Revenue: 1.34M (Actual) vs. 500.00K (Estimate) (168.20%)
Price Reaction: 2.34%(1-Day), 10.16%(5-Day)
FY2024Q4 (2025-03-19,After Hours):
EPS: (Actual) vs.-0.06 (Estimate) (%)
Revenue: 1.19M (Actual) vs. 3.00M (Estimate) (-60.33%)
Price Reaction: 0.56%(1-Day), -10.06%(5-Day)
Earnings Reaction
The chart below shows how PGEN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PGEN sees a +6.27% change in stock price 10 days leading up to the earnings, and a +7.19% change 10 days following the report. On the earnings day itself, the stock moves by +0.64%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed % on the day following the earnings release and then changed by 0% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Precigen Inc (PGEN) Q4 2024 Earnings Call Summary
Neutral
2025-03-19
The earnings call reflects mixed signals: strong cash position and anticipated demand for PRGN-2012 suggest positive sentiment. However, increased net loss, operational risks, and competitive pressures temper optimism. The Q&A highlights management's cautious communication about FDA interactions and market capture, which adds uncertainty. Considering these factors, the stock price is expected to remain stable.
Precigen Inc (PGEN) Q4 2024 Earnings Call Summary
Neutral
2025-03-19
The earnings call presents a mixed sentiment. While there are positive elements like strong cash position and potential revenue from PRGN-2012, there are concerns over increased net loss and supply chain risks. The Q&A highlights FDA interactions and market strategy, but management's evasiveness on key timelines adds uncertainty. Overall, the financial health and strategic outlook balance out the negatives, leading to a neutral sentiment prediction.
Precigen, Inc. (PGEN) Q2 2024 Earnings Call Summary
Negative
2024-08-14
The earnings call highlights significant financial concerns, including a large net loss and workforce reduction, which could affect operational capacity. The equity issuance and cash on hand provide limited runway. Positive aspects like the PRGN-2012 progress and global ambitions are overshadowed by vague management responses and market access challenges. The Q&A session reveals analyst concerns about FDA meetings and global strategy clarity. Overall, the negative financial outlook and uncertainties suggest a negative stock price movement in the short term.
People Also Watch

CRVS
Corvus Pharmaceuticals Inc
5.000
USD
+11.11%

SPOK
Spok Holdings Inc
18.760
USD
+0.48%

ASUR
Asure Software Inc
8.370
USD
+0.84%

CMPS
Compass Pathways PLC
4.290
USD
+1.66%

VACH
Voyager Acquisition Corp
10.400
USD
0.00%

CTNM
Contineum Therapeutics Inc
6.950
USD
+2.96%

ACRE
Ares Commercial Real Estate Corp
4.530
USD
+2.95%

BLDE
Blade Air Mobility Inc
4.390
USD
-2.44%

AUDC
AudioCodes Ltd
10.040
USD
+0.90%
FAQ

What were the key highlights of PGEN’s latest earnings report for FY2025Q2?
PGEN reported its FY2025Q2 earnings on 2025-08-13, showcasing a revenue of 0.00 against an estimate of 1,000K, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.14 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

How did PGEN’s stock price react after the FY2025Q2 earnings release?

What are the revenue and EPS estimates for PGEN for 2025/Q2?

How does PGEN’s stock price correlate with earnings forecast revisions?

What should investors expect from PGEN’s next earnings report?
